It is not controlled by a single enzyme
DPP-4 inhibitors which increase levels of GLP-1, a hormone that helps reduce blood sugar levels have been approved for treatment of type 2 diabetes since 2006
How Semaglutide enhances blood sugar control Semaglutide can potentially enhance the regulation of blood glucose in individuals with diabetes
The Market Disruption The GLP-1 market is projected to grow from $53.5 billion in 2024 to as much as $324 billion by 2035, according to a 2024 analysis from Fortune Business Insights
doi: 10.3390/ijms20246268 53 SahaSet al
BPC-157 may be worth exploring for: Men recovering from tendon, ligament, or muscle injuries Those experiencing chronic joint pain or inflammation Men on TRT who train intensely and want additional recovery support Individuals with gastrointestinal issues (gut inflammation, leaky gut, NSAID damage) Those interested in peptide therapy as part of a comprehensive wellness protocol Who Should Avoid BPC-157 Anyone with active cancer (BPC-157s angiogenic properties could theoretically promote tumor blood supply) Individuals allergic to any component of the peptide formulation Those unwilling to undergo medical supervision Anyone expecting BPC-157 to replace testosterone therapy for hypogonadism References Sikiric P, Seiwerth S, Rucman R, et al